This well-conducted review concluded that the efficacy of add-on omalizumab in patients with moderate to severe allergic asthma was accompanied by an acceptable safety profile. Despite some limitations of the included studies, the authors' conclusions and recommendations for research are appropriate.
Study selection
Placebo-controlled randomised trials (RCTs) that compared subcutaneous omalizumab with placebo as an add-on to corticosteroids in patients with allergic asthma were eligible for inclusion. The primary outcomes were reduction in inhaled and/or oral corticosteroids from baseline and asthma exacerbations; various secondary outcomes were considered.
Mean age of participants ranged from 8.6 to 49 years. Mean beclomethasone was 284 to 2,750μg/day. Severity of asthma was moderate to severe. Mean baseline immunoglobulin E (IgE) was 273 IU/mL (range 179 to 470 IU/mL). Most studies administered 0.016mg/kg/IgE omalizumab every two to four weeks; drug regimen in terms of run in and stabilisation phases and duration of treatment varied considerably across studies.
Two reviewers independently selected studies for the review; disagreements were resolved by consensus.
Assessment of study quality
Two reviewers independently assessed study quality using the five-point Cochrane risk of bias tool; disagreements were resolved by consensus.
Data extraction
Incidence of binary outcomes were extracted to enable calculation of relative risks (RR) and 95% confidence intervals (CI). For continuous outcomes, mean differences and 95% CI were extracted or calculated.
Two reviewers independently extracted data; disagreements were resolved by consensus.
Methods of synthesis
Pooled relative risks and weighted mean differences (WMD) with 95% CI were calculated using a random-effects model. Numbers needed to treat to benefit (NNTB) and harm (NNTH) were calculated. Heterogeneity was measured using the I 2 statistic (>60% was considered substantial). Sensitivity analyses were conducted on the primary outcome for those who experienced at least one asthma exacerbation and to investigate study quality. Subgroup analyses investigated age (<12 and ≥12 years), asthma severity (moderate/severe and severe) and duration of treatment (<24 weeks and ≥24 weeks). Publication bias was assessed using a funnel plot.
